Showing 1841-1850 of 2192 results for "".
- Decreased 10-Year Disability Progression in Multiple Sclerosis Seen With Autologous Hematopoietic Stem Cell Treatmenthttps://practicalneurology.com/news/decreased-10-year-disability-progression-in-multiple-sclerosis-seen-with-autologous-hematopoietic-stem-cell-treatment/2469482/A new study published in Neurology suggests autologous hematopoietic stem cell transplant (aHSCT) therapy for multiple sclerosis may have efficacy for preventing disability progression of multiple sclerosi
- Erenumab Reductions in Monthly Migraine Days Sustained for up to 2 Years In Episodic Migrainehttps://practicalneurology.com/news/erenumab-reductions-in-monthly-migraine-days-sustained-for-up-to-2-years-in-episodic-migraine/2469395/In the open-label extension period of a phase 2 study (NCT01952574), treatment with erenumab (Aimovig; Amgen, Thousand Oak, CA) resulted in sustained reductions in monthly migraine days (MMD) and use of acute migraine-specific medications (AMSM). Additionally, the safety profile was consistent wi
- Fenfluramine Consistently Reduces Seizures in Children and Young Adults with Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-consistently-reduces-seizures-in-children-and-young-adults-with-dravet-syndrome/2469374/A third phase 3 study (NCT02926898) further validates the significant reduction of convulsive seizures seen when individuals with Dravet syndrome (DS) receive fenfluramine (Fintepla; Zogenix Inc.,
- Cerebral Venous Thrombosis Incidence Is Increasinghttps://practicalneurology.com/news/cerebral-venous-thrombosis-incidence-is-increasing/2469362/A study published in Neurology, found that cerebral venous thrombosis (CVT) incidence is higher than previously reported and has also increased since 2006. Increased incidence was mainly in men and women more than age 45. Consistent with prior data, the incidence of CVT remained highest in younge
- New DNA-Plasmid Immunotherapy Treatment, in Combination with Cemiplimab, for Glioblastoma Results in 85% 1-Year Survival Ratehttps://practicalneurology.com/news/new-dna-plasmid-immunotherapy-treatment-in-combination-with-cemiplimab-for-glioblastoma-results-in-85-1-year-survival-rate/2469261/In a phase 1/2 clinical trial (NCT03491683), 85% (44 out of 52) of individuals newly diagnosed with glioblastoma multiforme (GBM) who received 2 new immunotherapeutic agents (INO-5401, INO-9012, I
- Children and Teens Caring for Their Parents with ALS Need More Education and Support From Other Youthhttps://practicalneurology.com/news/children-and-teens-caring-for-their-parents-with-als-need-more-education-and-support-from-other-youth/2469193/Children and teens with family members with amyotrophic lateral sclerosis (ALS) help with bathing, dressing, eating, and all types of caregiving activities. However, they may not have training or enough information about the disease. A study (published somewhere? if so state that; if not, s
- Children Treated Presymptomatically With Nusinersen Continue Surviving and Meeting Motor Milestones After 2 Years of Treatmenthttps://practicalneurology.com/news/children-treated-presymptomatically-with-nusinersen-continue-surviving-and-meeting-motor-milestones-after-2-years-of-treatment/2469037/As published in the journal Neuromuscular Disorders, 25 children who were genetically diagnosed with spinal muscular atrophy (SMA) and treated presymptomatically with nusinersen (Spinraza; Biogen, Cambridge,
- Ponesimod Superior to Teriflunomide for Relapsing Multiple Sclerosis in Phase 3 Trialhttps://practicalneurology.com/news/ponesimod-superior-to-teriflunomide-for-relapsing-multiple-sclerosis-in-phase-3-trial/2469015/In the phase 3 OPTIMUM study (NCT02425644), adults with relapsing multiple sclerosis (MS) treated with ponesimod (Janssen Pharmaceuticals, Titusville, NJ) had a 30.5% reduction in annualized relapse rate (ARR) compared with those treat
- Ofatumumab Superior to Teriflunomide for Relapsing Remitting Multiple Sclerosis in Phase 3 Head-to-Head Clinical Trialhttps://practicalneurology.com/news/ofatumumab-superior-to-teriflunomide-for-relapsing-remitting-multiple-sclerosis-in-phase-3-head-to-head-clinical-trial/2469007/The maker of ofatumumab (OMB157; Novartis, Basel, Switzerland) has announced results of 2 head-to-head phase 3 clinical studies (ASCLEPIOS I and II [NCT02792218 and NCT02792231<
- Remote Neuromodulation May Be Superior to Acute Medications for Migrainehttps://practicalneurology.com/news/remote-neuromodulation-may-be-superior-to-acute-medications-for-migraine/2468980/In a study published in The Journal of Headache and Pain remote electric neuromodulation (REN) for acute migraine treatment with the Nerivio device (Theranica; Netanya, Israel) was